One case of metastatic BC can cost up to C$ 516,415 (HR+/HER2+) for treatment, driven primarily by the cost of systemic therapy, compared to C$ 25,247 (TN) for stage I, a 20-fold increase in expense. The gene discussed is ERBB2; the disease is breast cancer.